Robert S. Fishman - 01 Sep 2022 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Reporting relationship: Chief Medical Officer
Issuer ticker: FDMT
Reported as of: 01 Sep 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Sep 2022, 20:42:21 UTC
Prior SEC filing: 03 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ August J. Moretti, Attorney-in-Fact for Robert Fishman

Key filing fact

Robert S. Fishman filed Form 4 for 4D Molecular Therapeutics, Inc. (FDMT) on 06 Sep 2022.

Key facts

This page summarizes Robert S. Fishman's Form 4 filing for 4D Molecular Therapeutics, Inc. (FDMT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Sep 2022, 20:42.

Change

Previous filing in this sequence was filed on 03 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FDMT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +60,000
Change %
Price: $0.000000
Shares after: 60,000
Date: 01 Sep 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 60,000
Exercise price: $8.04
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.